Clinically Significant Drug Interactions with Cholinesterase Inhibitors: A Guide for Neurologists

CNS Drugs

Volumn 17, Issue 13, 2003, Pages 947-963

  Bentué Ferrer, Danièle ^a   Tribut, Olivier ^a   Polard, Elisabeth ^b   Allain, Hervé ^a  

^a Inst de Rech Contre le Cancer IRCC   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALUMINUM MAGNESIUM HYDROXIDE; ANTACID AGENT; ANTIARRHYTHMIC AGENT; ANTIOXIDANT; AURANTIIN; CARBAMIC ACID DERIVATIVE; CHOLINESTERASE INHIBITOR; CIMETIDINE; CYTOCHROME P450 1A2; DONEPEZIL; EPASTIGMINE; ERYTHROMYCIN; FLUVOXAMINE; GALANTAMINE; HUPERZINE A; KETOCONAZOLE; MEMANTINE; METRIFONATE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PAROXETINE; PHYSOSTIGMINE; PSYCHOTROPIC AGENT; RISPERIDONE; RIVASTIGMINE; TACRINE; TYRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ABDOMINAL PAIN; AGITATION; ALZHEIMER DISEASE; ANOREXIA; AREA UNDER THE CURVE; ASTHENIA; BRADYCARDIA; CHEESE; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FATIGUE; FOOD DRUG INTERACTION; HUMAN; INSOMNIA; MUSCLE CRAMP; MUSCLE WEAKNESS; NAUSEA; NIGHTMARE; PANIC; PRIORITY JOURNAL; REVIEW; RHINITIS; TREMOR; URINE INCONTINENCE; VERTIGO; VOMITING; WEIGHT REDUCTION;

CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; NEUROLOGY;

EID: 0242403526     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200317130-00002     Document Type: Review

References (90)

1. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999; 341: 1670-9
2. Bentué-Ferrer D, Michel BF, Reymann JM, et al. Les nouveautés thérapeutiques pour la maladie d'Alzheimer. Rev Geriatr 2001; 26: 511-22
3. Allain H, Tribut O, Reymann JM, et al. Perpectives mé dicamenteuses dans la maladie d'Alzheimer. Ann Med Interne (Paris) 2001; 152: 527-32
4. Eggert A, Crismon ML, Ereshefsky L. Alzheimer's disease. In: Dipiro J, Talbet RL, Yee GC, et al., editors. Pharmacotherapy. 3rd ed. New York: Elsevier, 1997: 1325-44
5. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989; 262: 2551-6
6. Bachman DL, Wolf PA, Linn RT, et al. Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 1993; 43: 515-9
7. Sloan R. Drug interactions. In: Practical geriatric therapeutics. Oradell (NJ): Medical Economic Books, 1986: 39-50
8. Tribut O, Reymann JM, Polard E, et al. Interactions mé dicamenteuses chez le sujet âgé. Angéiologie 2000; 52: 25-38
9. Brawn L, Castleden C. Adverse drug reactions: an overview of special consideration in the management of the elderly patient. Drug Saf 1990; 5: 421-35
10. Allain H, Bentué-Ferrer D, Tribut O, et al. Drugs and vascular dementia. Dement Geriatr Cogn Disord 2003; 16: 1-6
11. Howard AK, Thomton AE, Altman S. Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol 2002; 16: 267-70
12. Weinstock M. Selectivity of cholinesterase inhibition: clinical implications for the treatment of Alzheimer's disease. CNS Drugs 1999; 12: 307-23
13. Greig NH, Utsuki T, Yu Q, et al. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase. Curr Med Res Opin 2001; 17: 159-65
14. Poirier J. Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl 2002; 127: 6-19
15. Imbimbo BP. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease. CNS Drugs 2001; 15: 375-90
16. Dooley M, Lamb HM. Donepezil: a review of its use in Alzheimer's disease. Drugs Aging 2000; 16: 199-226
17. Spencer CM, Noble S. Rivastigmine: a review of its use in Alzheimer's disease. Drugs Aging 1998; 13: 391-411
18. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000; 60: 1095-122
19. VanDenBerg CM, Kazmi Y, Jann MW. Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly. Drugs Aging 2000; 16: 123-38
20. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19: 465-80
21. Schachter AS, Davis KL. Guidelines for the appropriate use of cholinesterase inhibitors in patients with Alzheimer's disease. CNS Drugs 1999; 11: 281-8
22. Summers WK. Tacrine (THA, Cognex®). J Alzheimers Dis 2000; 2: 85-93
23. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-39
24. Grutzendler J, Morris JC. Cholinesterase inhibitors for Alzheimer's disease. Drugs 2001; 61: 41-52
25. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clin Ther 1998; 20: 634-47
26. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88
27. Ormrod D, Spencer C. Metrifonate: a review of its use in Alzheimer's disease. CNS Drugs 2000; 13: 443-67
28. Schmidt BH, Heinig R. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9 Suppl. 2: 15-9
29. Farlow MR, Cyrus PA. Metrifonate therapy in Alzheimer's disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials. Dement Geriatr Cogn Disord 2000; 11: 202-11
30. Clinical trials with metrifonate have been stopped by Bayer. Reactions 1998 Nov 14; 1 (727): 4
31. Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer's disease. Drugs Aging 1999; 14: 359-73
32. Bai DL, Tang XC, He XC. Huperzine A: a potential therapeutic agent for treatment of Alzheimer's disease. Curr Med Chem 2000; 7: 355-74
33. Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging 2001; 18: 853-62
34. Inglis F. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 2002; 127: 45-63
35. Bénéton C, Bentué-Ferrer D, Reymann JM. Les interactions médicamenteuses. Angéiologie 1997; 49: 67-78
36. Sadowski DC. Drug interactions with antacids: mechanisms and clinical significance. Drug Saf 1994; 11: 395-707
37. Neuvonen PJ, Kivisto KT. Enhancement of drug absorption by antacids: an unrecognised drug interaction. Clin Pharmacokinet 1994; 27: 120-8
38. Heinig R, Boettcher M, Herman-Gnjidic Z, et al. Effects of a magnesium/aluminium hydroxide-containing antacid, cimetidine or ranitidine on the pharmacokinetics of metrifonate and its metabolite DDVP. Clin Drug Invest 1999; 17: 67-77
39. Huang F, Lasseter KC, Janssens L, et al. Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together. J Clin Pharmacol 2002; 42: 1341-51
40. Janssen. Reminyl tablets: prescribing information. Turnhout-seweg: Janssen Pharmaceutica NV, 2000 Jul 11
41. Schmidt LE, Dalhoff K. Food-drug interactions. Drugs 2002; 62: 1481-502
42. Welty DF, Siedlik PH, Posvar EL, et al. The temporal effect of food on tacrine bioavailability. J Clin Pharmacol 1994; 34: 985-8
43. Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon™ (ENA 713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract 1996; 8: 109-16
44. Wrighton SA, VandenBranden M, Ring BJ. The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 1996; 24: 461-73
45. Meyer UA. Overview of enzymes of drug metabolism. J Pharmacokinet Biopharm 1996; 24: 449-59
46. Fontana RJ, deVries TM, Woolf TF, et al. Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol 1998; 46: 221-8
47. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61: 619-27
48. Larsen JT, Hansen LL, Spigset O, et al. Fluvoxamine is a potent inhibitor of tacrine metabolism in vivo. Eur J Clin Pharmacol 1999; 55: 375-82
49. Forgue ST, Reece PA, Sedman AJ, et al. Inhibition of tacrine oral clearance by cimetidine. Clin Pharmacol Ther 1996; 59: 444-9
50. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and cimetidine: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 25-9
51. Reece PA, Garnett WR, Rock WL, et al. Lack of effect of tacrine administration on the anticoagulant activity of warfarin. J Clin Pharmacol 1995; 35: 526-8
52. Laine K, Palovaara S, Tapanainen P, et al. Plasma tacrine concentrations are significantly increased by concomitant hormone replacement therapy. Clin Pharmacol Ther 1999; 66: 602-8
53. Welty D, Pool W, Woolf T, et al. The effect of smoking on the pharmacokinetics and metabolism of Cognex in healthy volunteers [abstract]. Pharm Res 1993; 10 Suppl. 10: S334
54. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36: 425-38
55. Schein JR. Cigarette smoking and clinically significant drug interactions. Ann Pharmacother 1995; 29: 1139-48
56. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. Ann Pharmacother 1994; 28: 744-51
57. Parke-Davis. Cognex (tacrine hydrochloride): prescribing information. Morris Plains (NJ): Parke-Davis, 1993
58. Tiseo PJ, Foley K, Friedhoff LT. Concurrent administration of donepezil HCl and theophylline: assessment of pharmacokinetic changes following multiple-dose administration in healthy volunteers. Br J Clin Pharmacol 1998; 46 Suppl. 1: 35-9
59. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. Br J Clin Pharmacol 1998; 46 Suppl. 1: 30-4
60. Carrier L. Donepezil and paroxetine: possible drug interaction [letter]. J Am Geriatr Soc 1999; 47: 1037
61. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998; 46 Suppl. 1: 45-50
62. Heinig R, Kitchin N, Rolan P. Disposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate. Clin Drug Invest 1999; 18: 151-9
63. Carcenac D, Martin-Hunvadi C, Kiesmann M, et al. Extrapyramidal syndrome induced by donepezil. Presse Med 2000; 29: 992-3
64. Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clin Neuropharmacol 1992; 15: 322-5
65. Bourke D, Druckenbrod RW. Possible association between donepezil and worsening Parkinson's disease. Ann Pharmacother 1998; 32: 610-1
66. McSwain ML, Forman LM. Severe parkinsonian symptom development on combination treatment with tacrine and haloperidol [letter]. J Clin Psychopharmacol 1995; 15: 284
67. Maany I. Adverse interaction of tacrine and haloperidol [letter]. Am J Psychiatry 1996; 153: 1504
68. Arai M. Parkinsonism onset in a patient concurrently using tiapride and donepezil. Intern Med 2000; 39: 863
69. Magnuson TM, Keller BK, Burke WJ. Extrapyramidal side effects in a patient treated with risperidone plus donepezil. Am J Psychiatry 1998; 155: 1458-9
70. Weiser M, Rotmensch HH, Korczyn AD, et al. A pilot, randomized, open-label trial assessing safety and pharmacokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances. Int J Geriatr Psychiatry 2002; 17: 343-6
71. Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12: 135-50
72. Edell WS, Tunis SL. Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients. Am J Geriatr Psychiatry 2001; 9: 289-97
73. Reynolds PL, Strayer SM. Neuroleptics for behavioral symptoms of dementia. J Fam Pract 2000; 49: 78-9
74. Company core data sheet. Paris: le Dictionnaire Vidal® édition, 2003
75. Allain H, Bentué-Ferrer D, Lieury A, et al. Beta-blockers and memory. BVS Europe 1996; 3: 5-14
76. Tiseo PJ, Rogers SL, Friedhoff LT. Co-administration of done-pezil and digoxin produces no pharmacokinetic or pharmacodynamic interactions [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: S252
77. Tiseo PJ, Perdomo CA, Friedhoff LT. Concurrent administration of donepezil HCl and digoxin: assessment of pharmacokinetic changes. Br J Pharmacol 1998; 46 Suppl. 1: 40-4
78. Polard E, Belliard S, Duclos R, et al. Malaise ou perte de connaissance et inhibiteurs de l'acétylcholinesterase. Therapie. In press
79. Lane G. Potential donepezil: succinylcholine interaction [letter]. Can J Hosp Pharm 1998; 51: 272
80. Heath ML. Donepezil, Alzheimer's disease and suxamethonium [letter]. Anaesthesia 1997; 52: 1018
81. Sprung J, Castellani WJ, Srinivasan V, et al. The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity. Anesth Analg 1998; 87: 1203-5
82. Morillo J, Demartini Ferrari A, Roca de Togores Lopez A. Interaction of donepezil and muscular blockers in Alzheimer's disease. Rev Esp Anestesiol Reanim 2003; 50: 97-100
83. Heath ML. Donepezil and succinylcholine [letter]. Anaesthesia 2003; 58: 202
84. Piecoro LT, Wermeling DP, Schmitt FA, et al. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy 1998; 18: 1129-32
85. Crismon ML. Pharmacokinetics and drug interactions of cholinesterase inhibitors administered in Alzheimer's disease. Pharmacotherapy 1998; 18 (2 Pt 2): 47S-54S
86. Hooten WM, Pearlson G. Delirium caused by tacrine and ibuprofen interaction [letter]. Am J Psychiatry 1996; 153: 842
87. Benveniste EN, Nguyen VT, O'Keefe GM. Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int 2001; 39: 381-91
88. Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. J Am Geriatr Soc 2000; 48: 1659-63
89. Grossberg GT, Stahelin HB, Messina JC. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications. Int J Geriat Psychiatry 2000; 15: 242-7
90. Schück S, Bentué-Ferrer D, Beaufils C, et al. Effets indésirables et médicaments de la maladie d'Alzheimer. Thérapie 1999; 54: 237-42